Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/FIS1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/FIS1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/FIS1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/FIS1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/FIS1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/FIS1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/FIS1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/FIS1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/FIS1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/FIS1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/FIS1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000974325 | Oral cavity | NEOLP | response to carbohydrate | 45/2005 | 253/18723 | 4.43e-04 | 4.00e-03 | 45 |
GO:003428425 | Oral cavity | NEOLP | response to monosaccharide | 41/2005 | 225/18723 | 4.69e-04 | 4.20e-03 | 41 |
GO:190357824 | Oral cavity | NEOLP | regulation of ATP metabolic process | 20/2005 | 87/18723 | 7.28e-04 | 5.97e-03 | 20 |
GO:000042231 | Oral cavity | NEOLP | autophagy of mitochondrion | 19/2005 | 81/18723 | 7.53e-04 | 6.12e-03 | 19 |
GO:006172631 | Oral cavity | NEOLP | mitochondrion disassembly | 19/2005 | 81/18723 | 7.53e-04 | 6.12e-03 | 19 |
GO:000974624 | Oral cavity | NEOLP | response to hexose | 39/2005 | 219/18723 | 1.00e-03 | 7.68e-03 | 39 |
GO:007132223 | Oral cavity | NEOLP | cellular response to carbohydrate stimulus | 31/2005 | 163/18723 | 1.07e-03 | 8.08e-03 | 31 |
GO:005105113 | Oral cavity | NEOLP | negative regulation of transport | 72/2005 | 470/18723 | 1.14e-03 | 8.49e-03 | 72 |
GO:007133323 | Oral cavity | NEOLP | cellular response to glucose stimulus | 29/2005 | 151/18723 | 1.30e-03 | 9.44e-03 | 29 |
GO:001095032 | Oral cavity | NEOLP | positive regulation of endopeptidase activity | 33/2005 | 179/18723 | 1.30e-03 | 9.46e-03 | 33 |
GO:000167824 | Oral cavity | NEOLP | cellular glucose homeostasis | 32/2005 | 172/18723 | 1.31e-03 | 9.48e-03 | 32 |
GO:190121431 | Oral cavity | NEOLP | regulation of neuron death | 52/2005 | 319/18723 | 1.37e-03 | 9.77e-03 | 52 |
GO:007133123 | Oral cavity | NEOLP | cellular response to hexose stimulus | 29/2005 | 153/18723 | 1.60e-03 | 1.12e-02 | 29 |
GO:190547731 | Oral cavity | NEOLP | positive regulation of protein localization to membrane | 22/2005 | 106/18723 | 1.72e-03 | 1.19e-02 | 22 |
GO:007132623 | Oral cavity | NEOLP | cellular response to monosaccharide stimulus | 29/2005 | 154/18723 | 1.78e-03 | 1.22e-02 | 29 |
GO:000863731 | Oral cavity | NEOLP | apoptotic mitochondrial changes | 22/2005 | 107/18723 | 1.95e-03 | 1.31e-02 | 22 |
GO:000974923 | Oral cavity | NEOLP | response to glucose | 36/2005 | 212/18723 | 3.52e-03 | 2.07e-02 | 36 |
GO:200105631 | Oral cavity | NEOLP | positive regulation of cysteine-type endopeptidase activity | 27/2005 | 148/18723 | 3.96e-03 | 2.26e-02 | 27 |
GO:005140232 | Oral cavity | NEOLP | neuron apoptotic process | 40/2005 | 246/18723 | 4.78e-03 | 2.62e-02 | 40 |
GO:190547531 | Oral cavity | NEOLP | regulation of protein localization to membrane | 30/2005 | 175/18723 | 6.34e-03 | 3.29e-02 | 30 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FIS1 | SNV | Missense_Mutation | novel | c.357N>C | p.Lys119Asn | p.K119N | Q9Y3D6 | protein_coding | tolerated(0.14) | benign(0.102) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FIS1 | SNV | Missense_Mutation | | c.349G>T | p.Ala117Ser | p.A117S | Q9Y3D6 | protein_coding | tolerated(0.08) | benign(0.429) | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR |
FIS1 | SNV | Missense_Mutation | novel | c.350C>T | p.Ala117Val | p.A117V | Q9Y3D6 | protein_coding | deleterious(0.05) | benign(0.41) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
FIS1 | SNV | Missense_Mutation | | c.439N>A | p.Val147Met | p.V147M | Q9Y3D6 | protein_coding | tolerated(0.58) | possibly_damaging(0.49) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FIS1 | SNV | Missense_Mutation | rs776529563 | c.430G>A | p.Gly144Arg | p.G144R | Q9Y3D6 | protein_coding | deleterious(0.03) | probably_damaging(0.964) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
FIS1 | SNV | Missense_Mutation | novel | c.130N>T | p.Arg44Trp | p.R44W | Q9Y3D6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
FIS1 | SNV | Missense_Mutation | | c.233N>T | p.Ala78Val | p.A78V | Q9Y3D6 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FIS1 | SNV | Missense_Mutation | novel | c.421N>A | p.Gly141Arg | p.G141R | Q9Y3D6 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
FIS1 | SNV | Missense_Mutation | novel | c.62N>G | p.Phe21Cys | p.F21C | Q9Y3D6 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
FIS1 | SNV | Missense_Mutation | novel | c.421G>A | p.Gly141Arg | p.G141R | Q9Y3D6 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-D1-A16Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |